title: Identifying EGFR mutations from SCLC patient plasma by mutant-enriched liquidchip technology.
abstract: BACKGROUND
  Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as erlotinib and gefitinib are targeted drugs for the kinase domain of EGFR. They are widely used for the treatment of non-small cell lung cancer (NSCLC). The EGFR exon 19 deletion mutation and the L858R mutation in exon 21 comprise approximately 90% of the somatic mutations in NSCLC patients that respond to EGFR TKI. Several recent studies have also reported that small cell lung cancer (SCLC) patients with EGFR mutations responded to gefitinib. Further study, however, has been limited due to the difficulty obtaining tumor specimens from SCLC patients.
  
  
  OBJECTIVE
  The aim of this study was to explore the EGFR mutation status in SCLC patients by plasma analysis.
  
  
  METHODS
  Plasma samples from SCLC patients were collected for mutant-enriched liquidchip (MEL) analysis to identify the EGFR mutations in exon 19 and 21.
  
  
  RESULTS
  The exon 19 deletion mutation was detected in one out of 35 patients (a female non-smoker). No exon 21 mutations were found.
  
  
  CONCLUSIONS
  A prevalence of EGFR mutations in SCLC is rare, and occurs most frequently in females and nonsmokers.
authors.affiliation: Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Hong-Yang
authors.initials: HY
authors.lastname: Lu
authors.affiliation: Department of Oncology, Xiangshan First People's Hospital, Xiangshan 315700, PRC.
authors.forename: Zhen-Yi
authors.initials: ZY
authors.lastname: Lu
authors.affiliation: Department of Traditional Chinese Medicine, Zhejiang Institute for Food and Drug Control, Hangzhou 310004, PRC.
authors.forename: Qiao-Yuan
authors.initials: QY
authors.lastname: Cheng
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Ju-Fen
authors.initials: JF
authors.lastname: Cai
authors.affiliation: Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Xiao-Jia
authors.initials: XJ
authors.lastname: Wang
authors.affiliation: Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Yi-Ping
authors.initials: YP
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Cai-Jin
authors.initials: CJ
authors.lastname: Lou
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Xin-Min
authors.initials: XM
authors.lastname: Yu
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Jing
authors.initials: J
authors.lastname: Qin
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Wei-Wu
authors.initials: WW
authors.lastname: Ye
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Lei
authors.initials: L
authors.lastname: Lei
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
authors.affiliation: Surexam bio-Tech co. Ltd., Guangzhou Technology Innovation Base, Science city, Guangzhou 510663, PRC.
authors.forename: Hui-Yi
authors.initials: HY
authors.lastname: Yang
authors.affiliation: Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, PRC.
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Mao
mesh_terms: D018288:Carcinoma, Small Cell / Q000097:blood / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction / Q000379:methods*
chemical_list: D066246:ErbB Receptors